Highly sensitive upregulation of apolipoprotein A-IV by peroxisome proliferator-activated receptor α (PPARα) agonist in human hepatoma cells

Biochemical Pharmacology

Volumn 74, Issue 12, 2007, Pages 1738-1746

  Nagasawa, Michiaki ^a   Akasaka, Yunike ^a   Ide, Tomohiro ^a   Hara, Tomoko ^a   Kobayashi, Naoki ^a   Utsumi, Mari ^a   Murakami, Koji ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Apolipoprotein; HDL; HepaRG; KRP; PPAR ; Triglyceride

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; CARNITINE PALMITOYLTRANSFERASE; ENOYL COENZYME A HYDRATASE; FATTY ACID BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN; KRP 101; LIPID; LIVER FATTY ACID BINDING PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PHOSPHOTRANSFERASE; PYRUVATE DEHYDROGENASE KINASE 4; SMALL INTERFERING RNA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LONG CHAIN ACYL COENZYME A DEHYDROGENASE;

ANIMAL EXPERIMENT; ARTICLE; CHO CELL; CONTROLLED STUDY; CULTURE MEDIUM; DOG; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; FATTY ACID OXIDATION; GENE EXPRESSION REGULATION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPID TRANSPORT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; APOLIPOPROTEINS A; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CHO CELLS; CRICETINAE; CRICETULUS; DNA PRIMERS; DOGS; HUMANS; MALE; OXIDATION-REDUCTION; PPAR ALPHA; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 36048929554     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.08.020     Document Type: Article

References (45)

1. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., et al. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
2. Keller H., and Wahli W. Peroxisome proliferator-activated receptors. Trends Endocrinol Metab 4 (1993) 291-296
3. A unified nomenclature system for the nuclear receptor superfamily. Cell 97 (1999) 161-163
4. Beck F., Plummer S., Senior P.V., Byrne S., Green S., and Brammar W.J. The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat. Proc R Soc Lond B: Biol Sci 247 (1992) 83-87
5. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137 (1996) 354-366
6. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46 (1997) 1319-1327
7. Schoonjans K., Staels B., and Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37 (1996) 907-925
8. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
9. Shepherd J. Mechanism of action of fibrates. Postgrad Med J 69 Suppl 1 (1993) S34-S41
10. Catapano A.L. Mode of action of fibrates. Pharmacol Res 26 (1992) 331-340
11. Fruchart J.C., and Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 42 (2006) 39-64
12. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., Heyman R.A., Briggs M., Deeb S., et al. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. Eur Mol Biol Org J 15 (1996) 5336-5348
13. Vu-Dac N., Gervois P., Jakel H., Nowak M., Bauge E., Dehondt H., et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 278 (2003) 17982-17985
14. Hertz R., Bishara-Shieban J., and Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 270 (1995) 13470-13475
15. Staels B., Vu-Dac N., Kosykh V.A., Saladin R., Fruchart J.C., Dallongeville J., et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95 (1995) 705-712
16. Malmendier C.L., Lontie J.F., Delcroix C., Dubois D.Y., Magot T., and De Roy L. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis 77 (1989) 139-149
17. Berthou L., Duverger N., Emmanuel F., Langouet S., Auwerx J., Guillouzo A., et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 97 (1996) 2408-2416
18. Staels B., and Auwerx J. Regulation of apoA-I gene expression by fibrates. Atherosclerosis 137 Suppl (1998) S19-S23
19. Vu-Dac N., Chopin-Delannoy S., Gervois P., Bonnelye E., Martin G., Fruchart J.C., et al. The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erbα mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 273 (1998) 25713-25720
20. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J.C., Staels B., et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96 (1995) 741-750
21. Qi C., Zhu Y., Pan J., Usuda N., Maeda N., Yeldandi A.V., et al. Absence of spontaneous peroxisome proliferation in enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase-deficient mouse liver. Further support for the role of fatty acyl CoA oxidase in PPARalpha ligand metabolism. J Biol Chem 274 (1999) 15775-15780
22. Wolfrum C., Ellinghaus P., Fobker M., Seedorf U., Assmann G., Borchers T., et al. Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein. J Lipid Res 40 (1999) 708-714
23. Louet J.F., Chatelain F., Decaux J.F., Park E.A., Kohl C., Pineau T., et al. Long-chain fatty acids regulate liver carnitine palmitoyltransferase I gene (L-CPT I) expression through a peroxisome-proliferator-activated receptor alpha (PPARalpha)-independent pathway. Biochem J 354 (2001) 189-197
24. Aoyama T., Ueno I., Kamijo T., and Hashimoto T. Rat very-long-chain acyl-CoA dehydrogenase, a novel mitochondrial acyl-CoA dehydrogenase gene product, is a rate-limiting enzyme in long-chain fatty acid beta-oxidation system. cDNA and deduced amino acid sequence and distinct specificities of the cDNA-expressed protein. J Biol Chem 269 (1994) 19088-19094
25. Motojima K. A metabolic switching hypothesis for the first step in the hypolipidemic effects of fibrates. Biol Pharm Bull 25 (2002) 1509-1511
26. Goldberg I.J., Scheraldi C.A., Yacoub L.K., Saxena U., and Bisgaier C.L. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem 265 (1990) 4266-4272
27. Jong M.C., Rensen P.C., Dahlmans V.E., van der Boom H., van Berkel T.J., and Havekes L.M. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res 42 (2001) 1578-1585
28. Murakami K., Ide T., Suzuki M., Mochizuki T., and Kadowaki T. Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor α. Biochem Biophys Res Commun 260 (1999) 609-613
29. Murakami K., Tobe K., Ide T., Mochizuki T., Ohashi M., Akanuma Y., et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ: effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 47 (1998) 1841-1847
30. Nagasawa M., Ide T., Suzuki M., Tsunoda M., Akasaka Y., Okazaki T., et al. Pharmacological characterization of a human-specific peroxisome proliferater-activated receptor alpha (PPARalpha) agonist in dogs. Biochem Pharmacol 67 (2004) 2057-2069
31. Staels B., van Tol A., Andreu T., and Auwerx J. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb 12 (1992) 286-294
32. Anderson S.P., Dunn C., Laughter A., Yoon L., Swanson C., Stulnig T.M., et al. Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver. Mol Pharmacol 66 (2004) 1440-1452
33. Utermann G., and Beisiegel U. Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quantification. Eur J Biochem 99 (1979) 333-343
34. Lefevre M., and Roheim P.S. Metabolism of apolipoprotein A-IV. J Lipid Res 25 (1984) 1603-1610
35. Elshourbagy N.A., Boguski M.S., Liao W.S., Jefferson L.S., Gordon J.I., and Taylor J.M. Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc Natl Acad Sci USA 82 (1985) 8242-8246
36. Ghiselli G., Krishnan S., Beigel Y., and Gotto Jr. A.M. Plasma metabolism of apolipoprotein A-IV in humans. J Lipid Res 27 (1986) 813-827
37. Cohen R.D., Castellani L.W., Qiao J.H., Van Lenten B.J., Lusis A.J., and Reue K. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest 99 (1997) 1906-1916
38. Weinstock P.H., Bisgaier C.L., Hayek T., Aalto-Setala K., Sehayek E., Wu L., et al. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice. J Lipid Res 38 (1997) 1782-1794
39. Fujimoto K., Cardelli J.A., and Tso P. Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation. Am J Physiol 262 (1992) G1002-G1006
40. Fujimoto K., Fukagawa K., Sakata T., and Tso P. Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. J Clin Invest 91 (1993) 1830-1833
41. Qi L., Liu S., Rifai N., Hunter D., and Hu F.B. Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes. Atherosclerosis 192 (2007) 204-210
42. Ostos M.A., Conconi M., Vergnes L., Baroukh N., Ribalta J., Girona J., et al. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 1023-1028
43. Akiyama T.E., Nicol C.J., Fievet C., Staels B., Ward J.M., Auwerx J., et al. Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines. J Biol Chem 276 (2001) 39088-39093
44. Lawrence J.W., Li Y., Chen S., DeLuca J.G., Berger J.P., Umbenhauer D.R., et al. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson. J Biol Chem 276 (2001) 31521-31527
45. Singh J.P., Kauffman R., Bensch W., Wang G., McClelland P., Bean J., et al. Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression. Mol Pharmacol 68 (2005) 763-768